Guests file in to the Novartis Institutes for Biomedical Research for some pre-event schmoozing.
Martin Seidel, NIBR’s global head of strategic alliances, gets things underway.
From left: Peter Barrett, Tom Hughes, and Bruce Booth share a laugh recounting Hughes’ initial disinterest in running Zafgen.
Never forget your notepad at one of these events, you just might learn something.
Robert Gould talks being pitched about Epizyme: “it was a fundamental area of biology, a fundamental opportunity, particularly in the field of cancer.” He was named the company’s CEO in 2010.
Not a seat in the house as Bay City Capital’s Carl Goldfischer talks the pros and cons of pushing for an IPO or a sale.
Though sporting the best shoes in the house, Kevin Starr (r.) gives more than just fashion lessons. Sage CEO Jeff Jonas looks on.
Jonas had the crowd rolling recounting his first pitch from Sage, and the “farkakt indications,” it first intended to pursue.
Only the healthiest grub for our attendees. This is a healthcare event after all.
Why would Epizyme go public? I mean come on, it’s way easier to sell.
Is this a drone strike? No, our photographer will find you from any angle.
How do you pull off a successful biotech IPO? With patience, preparation, and no fear of failure.
Last week, I recapped our latest biotech event, “Boston’s Life Science Disruptors.” Attendees at the Novartis Institutes for Biomedical Research got a behind-the-scenes look at the ups and downs faced by three local biotechs—Zafgen, Epizyme, and Sage Therapeutics—on their way to successful Nasdaq debuts.
Today, I’m circling back with a slideshow look at the proceedings, with a tip of the cap to Tyler Trahan for the photos.
Once again, thanks to our speakers, our event host Novartis and our sponsors BDO, Cubist Pharmaceuticals, Health Advances, Icon, Johnson & Johnson Innovation, and Mintz Levin Cohn Ferris Glovsky and Popeo. With that, on with the slideshow.
By posting a comment, you agree to our terms and conditions.
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins DiscoverySponsored · Special Report
Hyperinflation in rents is over
Hughes MarinoSponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Brex© 2007-2021, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
?__________dears 77dollors in one hours with xconomy —- Find it More __________??